Pathology Update: State-of-the-Art Diagnostic Approaches to Surgical Pathology is organized by American Society for Clinical Pathology (ASCP) and will be held from Jul 15 - 19, 2019 at Hyatt Regency Toronto, Toronto, Ontario, Canada.
Pathologists, Pathology Residents, and Pathologists’ Assistants.
33.75 CME Credits, 10.0 SAMs CME Credits.
Pathology Update provides a state-of-the-art overview of surgical pathology. The value of the course comes directly from the expertise of the presenters and the real-world insights that they provide for your day-to-day practice. Pathology Update 2016 offers an exciting blend of returning and new experts who will discuss breast, gynecologic, head, and neck, pulmonary, urologic, gastrointestinal, and dermatologic pathology, in addition to molecular and immunohistochemistry concepts and applications. Pathology Update will take you beyond the H&E to provide the latest knowledge about staging and tumor classification, prognostic factors, immunohistochemical profiles and molecular markers, important clinical trials, and novel therapeutic approaches.
Following this course, you will be able to:
• Apply the newly released 8th Edition staging to various type of tumors
• Discuss the features that allow separation of benign from malignant mesothelial proliferations; explain current issues in the diagnosis of lung cancer, and describe problem areas in interstitial lung disease.
• Accurately assign and report the Gleason score of prostatic adenocarcinoma using the current recommendations of the International Society of Urologic Pathology and describe the key pathologic features that should be included in a pathology report of urothelial carcinoma of the urinary bladder.
• Explain the relevance of molecular testing to diagnostic pathology and the meaning of testing results; discuss the influence of molecular testing on the diagnosis, disease surveillance, and therapeutic choices for various organ systems; describe in general the current guidelines for tumor types that will necessitate molecular testing; and discuss molecular alterations in lung, thyroid, and colorectal cancer and in gliomas, mesothelioma, and soft tissue tumors.
• Apply a judicious panel of immunohistochemistry (IHC) stains in the setting of an unknown tumor type; apply a directed panel of transcription-factor-centric immunostains to identify the site of origin for metastatic carcinoma of unknown primary; recognize potential pitfalls in IHC stain interpretation and apply best practices to IHC stain implementation in your laboratory.
• Discuss the diagnostic criteria for lesions of the thyroid, salivary glands, and mucosal lining of the upper aerodigestive tract and explain recurrent molecular alterations in head and neck neoplasia.
• Reduce/eliminate error in breast pathology diagnosis through an awareness of diagnostic pitfalls and the related resolutions, using conventional microscopy and appropriate adjunctive diagnostic techniques.
|Contact No. :||+1 800-267-2727
|Registration Type||End Date||Price|
|Non-Member - Final Fee||14 Jul,2019||USD 1494.00|
|Member - Final Fee||14 Jul,2019||USD 1149.00|
|Lab Professional or Resident - Final Fee||14 Jul,2019||USD 574.00|